Q:Isn't it the same as other topics (vitamins, glucose)? Reid: Except thousands of people going to their HCP #PMWC17
3:11pm January 25th 2017 via Twitter Web Client
Reid: Google query into ClinVar will waste a lot of physician's time. They'll push back again. #PMWC17
3:09pm January 25th 2017 via Twitter Web Client
Hagenkord: '08 position paper against it; '15 AMP changed to be in favor of DTC testing. ACGC '16 #PMWC17
Hagenkord: A 13x fold risk of prostate ca? Trying to say something clinical about it. Consumers wanted more info. #PMWC17
3:08pm January 25th 2017 via Twitter Web Client
Hagenkord: With GWAS all the rage, why not connect it to people? Uncomfortable to the medical community. #PMWC17
3:07pm January 25th 2017 via Twitter Web Client
Avey: Saw so many studies w/o statistical power. Scientists did a good job on what went into a report. Would do different now... #PMWC17
3:06pm January 25th 2017 via Twitter Web Client
Reid: Baylor banned 23andMe reports; physicians pushed back on people 'running amok' Hagenkord: "23andMe a great idea..." #PMWC17
3:05pm January 25th 2017 via Twitter Web Client
Billings: Unexpected results due to pleiotrophic effects; another problem is the db's are full of sick people. #PMWC17
3:02pm January 25th 2017 via Twitter Web Client
Hagenkord: No standards for 'elective genomics'. Starting the discussion. 60 genes vs 12 for cardio. #PMWC17
3:01pm January 25th 2017 via Twitter Web Client
Hagenkord: Testing of a sick vs healthy person? Cardiomyopathy: entire genes, a dx std. But for a healthy person? #PMWC17
3:00pm January 25th 2017 via Twitter Web Client
Hagenkord: FDA come a long way in the past 2y, forward looking, cautiously optimistc #PMWC17
2:59pm January 25th 2017 via Twitter Web Client
Hagenkord: Not a reason to not help when you can. Genetics has been held to a different std cp to other medical areas #PMWC17
2:58pm January 25th 2017 via Twitter Web Client
Reid: Challenges Hagenkord: Cautious people (eg ethicists) 'we should sequence then put the data in a cave, come back in 20y' #PMWC17
2:57pm January 25th 2017 via Twitter Web Client
Reid: AppleKit? Avey: Parkinson's first version was clumsy, 2nd version getting better. #PMWC17
2:56pm January 25th 2017 via Twitter Web Client
Hagenkord: Saliva-based, counseling, works through physicians. Trying to step into preventative genetics #PMWC17
2:55pm January 25th 2017 via Twitter Web Client
Hagenkord: Health-care system is so broken: a physician at Color, low-cost, easy-access hereditary cancer. W/Mary Claire-King #PMWC17
2:54pm January 25th 2017 via Twitter Web Client
Billings: Launching for ex-US, b/c of a large need, and regions of favorable regulation... #PMWC17
2:52pm January 25th 2017 via Twitter Web Client
Billings: Only interested in multi-generation families. Forward human genetics: the basic unit of trios, sibs #PMWC17
Billings: Have your exome done, have updates given to you over time, info being shared both ways. #PMWC17
2:51pm January 25th 2017 via Twitter Web Client
Billings: PlumCare is about families - genetic info over time, we only know about 10% of what an exome means. #PMWC17
2:50pm January 25th 2017 via Twitter Web Client
(Company Avey referred to is Oura https://t.co/f1KPtEb9ov #PMWC17 )
Data sources? Avey:Finnish co Aura partner, monitoring sleep, unannounced genetics co, uBiome. Opportunistic regarding Q's to answer #PMWC17
2:49pm January 25th 2017 via Twitter Web Client
Avey:Can we make it a beautiful and enriching experience for the participants? Designers, UX, a huge opportunity. #PMWC17
2:48pm January 25th 2017 via Twitter Web Client
Some mechanisms: how are you engaging? Avey:It is a design challenge more than anything. #PMWC17
2:47pm January 25th 2017 via Twitter Web Client
Hagenkord: The participant loves it; need to have the incumbent healthcare system and IRBs back on track to satify the consumer. #PMWC17
2:46pm January 25th 2017 via Twitter Web Client
Hagenkord: IRBs are well-intentioned, just gone too far; the modern world works differently; participatory research. #PMWC17
2:45pm January 25th 2017 via Twitter Web Client
Billings: IRBs? Avey: At 23andMe they didn't know what to say. Making more productive conversations impt #PMWC17
Avey: Fitbit early getting people excited about individual's data. Regulatory piece, an open question. People will drive this. #PMWC17
2:43pm January 25th 2017 via Twitter Web Client
Avey: A sick-care vs health-care world: a bigger mission than themselves. 23andMe: so many willing to volunteer their data. #PMWC17
2:42pm January 25th 2017 via Twitter Web Client
Hagenkord: In 1960, doctors wouldn't even tell pts they had cancer. Whether #PMINetwork, Genomes UK, Helix: more educated consumers #PMWC17
Billings: Quality (screening, early det, prevention) an unmet need, can save money and get better outcomes. #PMWC17
2:40pm January 25th 2017 via Twitter Web Client
Billings: Evolution of shared decision-making; can grade the pt-dr interaction; can inc satisfaction. Chance for prevention. #PMWC17
2:39pm January 25th 2017 via Twitter Web Client
Billings: More info for pts on the web, enabling people. Value: education (a good thing); more precision #PMWC17
2:38pm January 25th 2017 via Twitter Web Client
Billings: 20% respond to immunoRx; time w/experts decrease, expectations increase. At the end of medical paternalism #PMWC17
2:37pm January 25th 2017 via Twitter Web Client
Billings: What's the purpose and value? There's more to know, thus pts have more to lose in the interaction. #PMWC17
2:36pm January 25th 2017 via Twitter Web Client
Four topics: Purpose and Value, Some mechanisms, Challenges and barriers, Predictions. #PMWC17
Other panelists: Linda Avey (Curios, 23andMe), Paul Billings (PlumCare), Jill Hagenkord (Color Genomics) #PMWC17
2:35pm January 25th 2017 via Twitter Web Client
Clifford Reid (Genos Research) Patient Power: the Changing Role of Individuals #PMWC17 These are more than consumers, less than patients
2:33pm January 25th 2017 via Twitter Web Client
Rittenhouse: Conclude: Sens 75%-92%, Spec 100%; 15% no need for repeat tumor tissue biopsy. #PMWC17
2:22pm January 25th 2017 via Twitter Web Client
Rittenhouse: Insuff for genomic testing: 7/27. Another 7: had variety of drivers via tissue NGS #PMWC17
2:20pm January 25th 2017 via Twitter Web Client
Rittenhouse: At Dx with radiography (adv NSCLC), EGFR det in plasma in 15% of cases. (23/27 EGFR-) #PMWC17
Rittenhouse: Another high MET ampl, confirmed by FISH, alt mech of resistance. #PMWC17
2:19pm January 25th 2017 via Twitter Web Client
Rittenhouse: Value of tissue biopsy: one tranformed to small cell carcinoma, where 2 copy deletion of RB, PTEN #PMWC17
2:18pm January 25th 2017 via Twitter Web Client
Rittenhouse:EGFR mut detected in plasma in 75% of cases. 28 cases; n=7 EGFR-. 1 T790M in tissue not plasma #PMWC17
2:17pm January 25th 2017 via Twitter Web Client
Rittenhouse: EGFR+ in plasma, initiate targeted Rx; EGFR- goes to tissue sampling for EGFR or other #PMWC17
2:16pm January 25th 2017 via Twitter Web Client
Rittenhouse: Set min threshold of 3 positive droplets. Showed implementation in clin practice. #PMWC17
2:15pm January 25th 2017 via Twitter Web Client
Rittenhouse: Looked at EGFR Ex19del via dPCR, also L858R and T790M. Showed not great sens (70-90%) but 100% spec #PMWC17
2:14pm January 25th 2017 via Twitter Web Client
Rittenhouse: DFCI collected plasma with tissue; std genotyping of tissue and ctDNA. '14 Oxnard ref https://t.co/8wYNLn7N37 #PMWC17
2:12pm January 25th 2017 via Twitter Web Client
Rittenhouse: erlotinib-treted pt shown; day 4 T790M shown. day 25 tissue genotyping shown T790M, day 31 osimertinib responder #PMWC17
2:11pm January 25th 2017 via Hootsuite
Rittenhouse: Safety, cost, logistics, TAT: all problematic, so plasma testing attractive. #PMWC17
2:10pm January 25th 2017 via Hootsuite
